Compare HAE & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HAE | NAMS |
|---|---|---|
| Founded | 1971 | 2019 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.1B |
| IPO Year | 1991 | N/A |
| Metric | HAE | NAMS |
|---|---|---|
| Price | $80.37 | $35.52 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 10 |
| Target Price | ★ $84.38 | $45.80 |
| AVG Volume (30 Days) | 854.6K | ★ 1.1M |
| Earning Date | 11-06-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 42.54 | N/A |
| EPS | ★ 3.44 | N/A |
| Revenue | ★ $1,327,850,000.00 | $35,243,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.01 | N/A |
| P/E Ratio | $24.30 | ★ N/A |
| Revenue Growth | N/A | ★ 4.91 |
| 52 Week Low | $47.32 | $14.06 |
| 52 Week High | $87.32 | $42.00 |
| Indicator | HAE | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | 60.16 | 44.82 |
| Support Level | $82.30 | $34.59 |
| Resistance Level | $87.32 | $36.60 |
| Average True Range (ATR) | 2.21 | 1.83 |
| MACD | -0.91 | -0.38 |
| Stochastic Oscillator | 19.56 | 13.37 |
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company primarily emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.